A Sigyn Therapeutics apresentará sua tecnologia CardioDialysisTM no evento LD Micro em 21 de outubro de 2025, visando riscos de ataque cardíaco e derrame. Sigyn Therapeutics to present its CardioDialysis™ tech at LD Micro event on Oct. 21, 2025, targeting heart attack and stroke risks.

A Sigyn Therapeutics (OTCQB: SIGY) apresentará no 19o evento anual LD Micro Main Event em 21 de outubro de 2025, em San Diego, apresentando sua tecnologia CardioDialysisTM, que tem como alvo lipoproteínas e inflamação prejudiciais ligadas a ataques cardíacos e derrames. Sigyn Therapeutics (OTCQB: SIGY) will present at the 19th annual LD Micro Main Event on October 21, 2025, in San Diego, showcasing its CardioDialysis™ technology, which targets harmful lipoproteins and inflammation linked to heart attacks and strokes. O CEO Jim Joyce destacará o pipeline da empresa, incluindo ImmunePrepTM, ChemoPrepTM e ChemoPureTM, com o objetivo de melhorar os tratamentos contra o câncer. CEO Jim Joyce will highlight the company’s pipeline, including ImmunePrep™, ChemoPrep™, and ChemoPure™, aimed at enhancing cancer treatments. O evento conta com cerca de 120 empresas de pequeno porte e oferece acesso virtual. The event features around 120 small-cap companies and offers virtual access.